Management Team

Nader Yaghoubi, M.D., Ph.D.
President, Chief Executive Officer and Co-Founder

Dr. Yaghoubi has over 20 years of experience in the creation, operations and financing of life science companies. Before starting PathMaker Neurosystems, he established, as President and Founding CEO, Symbiotix Biotherapies, a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome. Prior to that, he was the first employee at Selecta Biosciences (Nasdaq:SELB) and BIND Therapeutics (Nasdaq:BIND), where he worked with the founders to launch the companies and establish operations and corporate development. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and earlier completed an internship at Advent International.  Earlier, he was a Health Care Entrepreneurship Fellow at Boston University, and served as a resident in the Department of Surgery at Lenox Hill Hospital in New York. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine, and did his undergraduate studies in Biochemistry at the University of Arizona. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued US patents, received one of the University’s highest awards for dissertational research, and was the basis of a venture-backed biotechnology company focused on neuroscience. He is extensively involved in mentoring young companies, and has served/serves as a mentor, advisor and reviewer with MBC’s MassCONNECT program, Mass Life Sciences Center programs and numerous international and university business plan competitions.

Jake Maslow, J.D.
Executive Vice President and Chief Intellectual Property Officer

Jake Maslow has 30 years of experience in various aspects of entrepreneurialism and IP commercialization, including recognition of innovation and commercial opportunity in new technologies, assisting startups and business formation, managing team formation and strategic growth, fund raising, strategic partnering, high-tech new product development and marketing, university licensing, and corporate and IP law. He was a former Director of the CUNY Technology Commercialization Office and was former Assistant Director of MIT Patents and Technology Licensing Office. Jake has been co-founder of several startups based on technologies out of MIT. As co-founder and CEO of Synkinetics, Inc., Jake successfully built a high-tech engineering company based on a proprietary high precision drive system for industrial and military applications, securing sponsorship of several leading F-500 companies, and supported by 30 angel investors, while generating substantial federal and commercial grants and revenues. As Co-founder and IP counsel / Strategic Advisor of Sionex Corporation, Jake introduced successful VC investment to support development of state-of-the-art lab-on-a-chip for real-time chemical detection; while working closely with C-level engineering and marketing to build substantial IP portfolio and to secure market entry; He is a graduate of Columbia University (CC’73, PS) and Brooklyn Law School (Juris Doctorate ‘76), and is a member of the New York and Massachusetts Bar and a registered US patent attorney. Jake also is an Air Force veteran, having graduated USAF Radar Electronics School (1968) and served as radar technician for the F4 Phantom Jet.

Nandini Murthy, M.S.
Vice President of Regulatory Affairs

Nandini Murthy joined PathMaker Neurosystems with responsibility for assuring compliance with worldwide regulatory requirements regarding PathMaker’s medical devices. She brings over 25 years of expertise in regulatory affairs, clinical and quality assurance functions with multiple device specialties, including neurology, cardiology, radiology and diagnostics. She serves as Principal of ENEM Consulting LLC, which provides clinical and regulatory consulting services to novel Class II and Class III diagnostic and therapeutic devices and drug-device combination products. Previously, she served as Vice-President, Clinical, Quality and Regulatory Affairs at InfraReDx and Vice-President, Regulatory Affairs and Quality Systems at Cyberkinetics Neurotechnology Systems, where she led regulatory submissions on the BrainGate BCI technology. She has also led regulatory efforts at various client companies, including for BCI, neurostimulation, neuromonitoring and digital therapeutic devices, developing regulatory strategy, clinical trials design, leading presubmission meetings and compilation of premarket filings. Throughout her career, Nandini Murthy has been involved in authoring numerous FDA submissions, including original PMAs, original HDE, original IDEs, PMA and IDE Supplements and 510(k)s for novel products, as well as designing and executing complex clinical trials. She holds a B.S. in Chemistry and Environmental Science from Bangalore University, India and a M.S. in Environmental Science from University of Massachusetts, Boston.

Zaghloul Ahmed, Ph.D. – Professor and Chairman, Department of Physical Therapy and Professor, Center for Developmental Neuroscience, CUNY
Scientific Founder, Consultant and SAB member

Dr. Zaghloul Ahmed, Chairman of the Department of
Physical Therapy, is a Neuroscience and Motor Control Professor at the College of Staten Island/CUNY, and is known for his research in bioelectronic medicine, which has significant practical implications. His research focuses on the innovative application of therapeutic strategies based on electrical and magnetic stimulation. He studies the modulatory effects of different forms of electromagnetic stimulation applied to the brain, spinal cord and peripheral organs. His goal is to characterize the short- and long-term physiological and therapeutic effects of these interventions and to delineate their mechanisms of action. To achieve this, he is studying the impact of these interventions in various model systems, from single cells to animal models to humans. His current areas of application are spinal cord injury, stroke and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The latest focus of the Ahmed lab is to study the effects of multi-site direct current stimulation on disease progression in ALS mouse models, offering hope for improved treatments and outcomes for people with ALS.